Effects of Flibanserin on Subdomain Scores of the Female Sexual Function Index in Women With Hypoactive Sexual Desire Disorder

Articles

Effects of Flibanserin on Subdomain Scores of the Female Sexual Function Index in Women With Hypoactive Sexual Desire DisorderIntroduction: Flibanserin treatment increases sexual desire and satisfying sexual events while decreasing distress in certain women diagnosed with acquired, generalized hypoactive sexual desire disorder (HSDD). Additional aspects of sexual function and the time course of response have…

Flibanserin for premenopausal hypoactive sexual desire disorder: Pooled analysis of clinical trials

Articles

Flibanserin for premenopausal hypoactive sexual desire disorder: Pooled analysis of clinical trialsBackground: Flibanserin, a 5-hydroxytryptamine 5-HT 1A  agonist and 5-HT 2A  antagonist, is indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This post hoc analysis assessed pooled efficacy and safety data for flibanserin in premenopausal women with HSDD.…

Effects of alcohol administered with flibanserin in healthy premenopausal women: A randomized, double-blind, single-dose crossover study

Articles

Effects of alcohol administered with flibanserin in healthy premenopausal women: A randomized, double-blind, single-dose crossover studyIntroduction: Flibanserin is approved in the United States and Canada for the treatment of hypoactive sexual desire disorder in premenopausal women. Aim: The purpose of this trial was to evaluate the safety of concomitant administration of flibanserin with alcohol. Methods:…

Safety and tolerability of evening ethanol consumption and bedtime administration of flibanserin in healthy premenopausal female subjects

Articles

Safety and tolerability of evening ethanol consumption and bedtime administration of flibanserin in healthy premenopausal female subjectsIntroduction: Flibanserin, a treatment for hypoactive sexual desire disorder, carries warnings for increased risk of severe hypotension and syncope when used with alcohol. However, these warnings are not informed by studies that used flibanserin’s recommended bedtime dosing because previous…

Effects of timing of flibanserin administration relative to alcohol intake in healthy premenopausal women: A randomized, double-blind, crossover study

Articles

Effects of timing of flibanserin administration relative to alcohol intake in healthy premenopausal women: A randomized, double-blind, crossover studyIntroduction: Flibanserin is approved in the United States and Canada for the treatment of acquired, generalized, hypoactive sexual desire disorder in premenopausal women. Sedation-related side effects are among the most prevalent adverse events. Although infrequent, hypotension and…

Effect of flibanserin treatment on body weight in premenopausal and postmenopausal women with hypoactive sexual desire disorder: a post hoc analysis

Articles

Effect of flibanserin treatment on body weight in premenopausal and postmenopausal women with hypoactive sexual desire disorder: a post hoc analysisBackground: Flibanserin, a 5-HT 1A  agonist and 5-HT 2A  antagonist, is indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This post hoc analysis evaluated the effect of flibanserin…

Evaluation of flibanserin safety: Comparison with other serotonergic medications

Articles

Evaluation of flibanserin safety: Comparison with other serotonergic medicationsIntroduction: Flibanserin, a multifunctional serotonin agonist and antagonist, is approved by the U.S. Food and Drug Administration (FDA) for treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women. During the FDA’s review of flibanserin, concerns were raised about the risks of hypotension, syncope, and sedation-related…

Safety of flibanserin in women treated with antidepressants: a randomized, placebo-controlled study

Articles

Safety of flibanserin in women treated with antidepressants: a randomized, placebo-controlled studyBackground: Depression is often associated with sexual dysfunction, and pharmacologic treatment for hypoactive sexual desire disorder can be considered in women receiving treatment for depression. Aim: To evaluate the safety of flibanserin in women treated for depression with selective serotonin reuptake inhibitors or serotonin…

Flibanserin for hypoactive sexual desire disorder: an open-label safety study

Articles

Flibanserin for hypoactive sexual desire disorder: an open-label safety studyBackground: To evaluate the safety of flibanserin in premenopausal and naturally postmenopausal women with hypoactive sexual desire disorder (HSDD) in an open-label extension (OLE) study. Aim: To examine the safety and tolerability of flibanserin 100 mg once daily at bedtime in the treatment of premenopausal and…